Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.55 |
| ▸ | FNTB | P49356 | 2/20 | 0.55 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320517 | 0.85 | FNTA (0.67) | FNTAFNTBPGGT1BMAOB | |
| SCHEMBL3303399 | 0.81 | FNTA (0.56) | FNTAFNTBPGGT1BMAOBXDH | |
| SCHEMBL3308484 | 0.80 | CYP19A1 (0.53) | FNTAFNTBPGGT1BMAOBXDH | |
| SCHEMBL3320288 | 0.78 | ATM (0.52) | FNTAFNTBPGGT1BMAOB | |
| SCHEMBL3865512 | 0.78 | MAOB (0.77) | FNTAFNTBPGGT1BMAOBXDH | |
| SCHEMBL28185508 | 0.78 | MAOB (0.58) | FNTAFNTBPGGT1BMAOBXDH | |
| SCHEMBL3319334 | 0.77 | MAOB (0.56) | FNTAFNTBPGGT1BMAOBXDH | |
| SCHEMBL2700393 | 0.77 | MAOB (0.56) | FNTAFNTBPGGT1BMAOBXDH | |
| SCHEMBL15831939 | 0.77 | MAOB (0.56) | FNTAFNTBPGGT1BMAOBXDH | |
| SCHEMBL551837 | 0.77 | FFAR1 (0.67) | FNTAFNTBPGGT1BMAOBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | MARTINEZ-PEREZ JOSE ANTONIO | 2010-04-15 | — | — | US | disclosed |
| EP-2166003-A1 | Excitatory amino acid receptor antagonists | Eli Lilly & Company (US) | 2010-03-24 | — | — | EP | disclosed |
| US-7205313-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY | 2004-07-15 | — | — | US | disclosed |
| EP-1368032-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003024453-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | FNTA 2799/4885FNTB 4172/4885PGGT1B 2424/4885 |
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | SLC1A2, SLC1A1, GRIN1 | FNTA 2799/4885FNTB 4172/4885PGGT1B 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.